Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study

被引:97
作者
Haupt, Thomas Huneck [1 ]
Petersen, Janne [1 ]
Ellekilde, Gertrude [2 ]
Klausen, Henrik Hedegaard [1 ]
Thorball, Christian Wandall [1 ]
Eugen-Olsen, Jesper [1 ]
Andersen, Ove [1 ]
机构
[1] Copenhagen Univ Hosp Hvidovre, Clin Res Ctr, DK-2650 Hvidovre, Denmark
[2] Copenhagen Univ Hosp Hvidovre, Acute Med Unit, DK-2650 Hvidovre, Denmark
来源
CRITICAL CARE | 2012年 / 16卷 / 04期
关键词
PLASMINOGEN-ACTIVATOR RECEPTOR; SOLUBLE UROKINASE RECEPTOR; PREDICTS MORTALITY; SERUM LEVEL; POPULATION;
D O I
10.1186/cc11434
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Introduction: Soluble urokinase plasminogen activator receptor (suPAR) is the soluble form of the membrane-bound receptor (uPAR) expressed predominantly on various immune cells. Elevated plasma suPAR concentration is associated with increased mortality in various patient groups, and it is speculated that suPAR is a low-grade inflammation marker reflecting on disease severity. The aim of this prospective observational study was to determine if the plasma concentration of suPAR is associated with admission time, re-admission, disease severity/Charlson Comorbidity Index Score, and mortality. Methods: We included 543 patients with various diseases from a Danish Acute Medical Unit during a two month period. A triage unit ensured that only medical patients were admitted to the Acute Medical Unit. SuPAR was measured on plasma samples drawn upon admission. Patients were followed-up for three months after inclusion by their unique civil registry number and using Danish registries to determine admission times, readmissions, International Classification of Diseases, 10th Edition (ICD-10) diagnoses, and mortality. Statistical analysis was used to determine suPAR's association with these endpoints. Results: Increased suPAR was significantly associated with 90-day mortality (4.87 ng/ml in survivors versus 7.29 ng/ml in non-survivors, P < 0.0001), higher Charlson Score (P < 0.0001), and longer admission time (P < 0.0001), but not with readmissions. The association with mortality remained when adjusting for age, sex, C-reactive protein (CRP), and Charlson Score. Furthermore, among the various Charlson Score disease groups, suPAR was significantly higher in those with diabetes, cancer, cardiovascular disease, and liver disease compared to those without comorbidities. Conclusions: SuPAR is a marker of disease severity, admission time, and risk of mortality in a heterogeneous cohort of patients with a variety of diseases. The independent value of suPAR suggests it could be of value in prognostic algorithms.
引用
收藏
页数:9
相关论文
共 20 条
[1]   Soluble Urokinase Plasminogen Activator Receptor is Associated With Progressive Liver Fibrosis in Hepatitis C Infection [J].
Berres, Marie-Luise ;
Schlosser, Beate ;
Berg, Thomas ;
Trautwein, Christian ;
Wasmuth, Hermann E. .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2012, 46 (04) :334-338
[2]   The urokinase receptor: Focused cell surface proteolysis, cell adhesion and signaling [J].
Blasi, Francesco ;
Sidenius, Nicolai .
FEBS LETTERS, 2010, 584 (09) :1923-1930
[3]  
Christensen Steffen, 2011, Clin Epidemiol, V3, P203, DOI 10.2147/CLEP.S20247
[4]   Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population [J].
Eugen-Olsen, J. ;
Andersen, O. ;
Linneberg, A. ;
Ladelund, S. ;
Hansen, T. W. ;
Langkilde, A. ;
Petersen, J. ;
Pielak, T. ;
Moller, L. N. ;
Jeppesen, J. ;
Lyngbaek, S. ;
Fenger, M. ;
Olsen, M. H. ;
Hildebrandt, P. R. ;
Borch-Johnsen, K. ;
Jorgensen, T. ;
Haugaard, S. B. .
JOURNAL OF INTERNAL MEDICINE, 2010, 268 (03) :296-308
[5]  
Eugen-Olsen J, 2002, INT J TUBERC LUNG D, V6, P686
[6]   suPAR - a future risk marker in bacteremia [J].
Eugen-Olsen, Jesper .
JOURNAL OF INTERNAL MEDICINE, 2011, 270 (01) :29-31
[7]   Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study [J].
Huttunen, R. ;
Syrjanen, J. ;
Vuento, R. ;
Hurme, M. ;
Huhtala, H. ;
Laine, J. ;
Pessi, T. ;
Aittoniemi, J. .
JOURNAL OF INTERNAL MEDICINE, 2011, 270 (01) :32-40
[8]   Improved accuracy of co-morbidity coding over time after the introduction of ICD-10 administrative data [J].
Januel, Jean-Marie ;
Luthi, Jean-Christophe ;
Quan, Hude ;
Borst, Francois ;
Taffe, Patrick ;
Ghali, William A. ;
Burnand, Bernard .
BMC HEALTH SERVICES RESEARCH, 2011, 11
[9]   Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients [J].
Koch, Alexander ;
Voigt, Sebastian ;
Kruschinski, Carsten ;
Sanson, Edouard ;
Dueckers, Hanna ;
Horn, Andreas ;
Yagmur, Eray ;
Zimmermann, Henning ;
Trautwein, Christian ;
Tacke, Frank .
CRITICAL CARE, 2011, 15 (01)
[10]   Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor [J].
Kofoed, K. ;
Eugen-Olsen, J. ;
Petersen, J. ;
Larsen, K. ;
Andersen, O. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2008, 27 (05) :375-383